ondansetron intravenous / Generic mfg. - LARVOL DELTA

Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Baylor College of Medicine | Active, not recruiting ➔ Completed | Trial completion date: Sep 2027 ➔ Jul 2026

Trial completion • Trial completion date • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Effect of Ondansetron on Patient Tolerance, Efficacy and Endoscopist Workload in Unsedated Endoscopy for Upper Gastrointestinal Bleeding (clinicaltrials.gov) - P4 | N=80 | Completed | Sponsor: Peking Union Medical College Hospital | Not yet recruiting ➔ Completed

Trial completion • Gastroenterology

Comparison of Intravenous Ondansetron and Low Dose Ketamine in Preventing Post Spinal Shivering (clinicaltrials.gov) - P=N/A | N=180 | Completed | Sponsor: Mayo Hospital Lahore | Initiation date: Jan 2020 ➔ Jul 2020

Trial initiation date

Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery (clinicaltrials.gov) - P2 | N=276 | Active, not recruiting | Sponsor: Instituto do Cancer do Estado de São Paulo | Recruiting ➔ Active, not recruiting

Enrollment closed • Gynecology

Time to First Rescue Antiemetic With Ondansetron Plus Metoclopramide Versus Dexamethasone Plus Metoclopramide for PONV Prophylaxis in Laparoscopic Cholecystectomy (clinicaltrials.gov) - P4 | N=264 | Recruiting | Sponsor: Faisalabad Medical University | Not yet recruiting ➔ Recruiting

Enrollment open • Head-to-Head

Dexamethasone Versus Ondansetron for Preventing Post-Spinal Hypotension in Preeclampsia (clinicaltrials.gov) - P4 | N=110 | Not yet recruiting | Sponsor: Assiut University

New P4 trial • Anesthesia • Gynecology • Hypotension

Food protein-induced enterocolitis syndrome in Spanish children: Results from a multicentre prospective study. (PubMed, J Pediatr Gastroenterol Nutr) - "Most children reacted to a single offending food. CM remains the most frequent trigger, although hen's egg and fish are also relevant. Improved clinical awareness may have contributed to earlier diagnosis."

Journal • Allergy • Food Hypersensitivity • Gastrointestinal Disorder • Hypotension • Immunology • Pediatrics

Ondansetron versus gabapentin in preventing postoperative nausea and vomiting after laparoscopic sleeve gastrectomy: a randomized study. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - P3 | "In this double-blind placebo controlled parallel study, 100 morbidly obese patients who were scheduled for LSG were randomized into two groups; group 1 (n = 50) which received intravenous ondansetron 8 mg before surgery and group 2 (n = 50) which received 600 mg oral gabapentin an hour before the anticipated time of surgery. Pain intensity was significantly lower in gabapentin group at 0-2 h, 6 h, and 12 h, but not at 24 or 48 h. Based on the safety profile and known analgesic property, gabapentin could represent a cost-effective prophylactic agent for PONV in patients undergoing LSG. Clinical trial registration: ClinicalTrials.gov Identifier: NCT05620641 (11/11/2022)."

Journal • Gastrointestinal Disorder • Obesity • Pain

Sleep Quality - Comparing the Effect of Ondansetron or Dexamethasone Given as Routine Prophylaxis Intraoperatively to Prevent Post Operative Nausea and Vomiting (SCORPION) (clinicaltrials.gov) - P4 | N=500 | Not yet recruiting | Sponsor: Telethon Kids Institute

New P4 trial • Anesthesia • Pediatrics

Haloperidol-Ondansetron versus Dexamethasone-Ondansetron for Prevention of Postoperative Nausea and Vomiting after Laparoscopic Gynecological Surgery: A Randomized Double-Blind Non-Inferiority Trial. (PubMed, J Perianesth Nurs) - "Haloperidol-ondansetron is non-inferior to dexamethasone-ondansetron for PONV prophylaxis after laparoscopic gynecological surgery. Lower early postoperative pain scores were observed with haloperidol-ondansetron, although this exploratory finding should be interpreted cautiously. The regimen may be considered an alternative in patients for whom corticosteroid use is undesirable."

Clinical • Head-to-Head • Journal • Anesthesia • Cardiovascular • CNS Disorders • Gynecology • Pain

Prophylactic Efficacy of Intravenous Nefopam Versus Ondansetron in Preventing Post-Spinal Shivering in Parturients Undergoing Elective Caesarean Section: A Double-Blind Randomised Controlled Trial. (PubMed, Niger Med J) - "Group N received intravenous nefopam (0.15 mg/kg), Group O received intravenous ondansetron (0.1 mg/kg), and Group P received 10 mL of normal saline as a placebo...Side effects and the need for rescue medication (intravenous pethidine 0.5 mg/kg) were also recorded...Intravenous nefopam and ondansetron are similarly effective in preventing post-spinal shivering and reducing rescue analgesia requirements during caesarean section under spinal anaesthesia. Ondansetron showed better antiemetic effect, while nefopam was associated with mild injection-site discomfort."

Journal • Review • Anesthesia • Obstetrics • Pain

Successful Management of Refractory Cannabinoid Hyperemesis Syndrome With Topical Capsaicin: A Case Report With Proposed Mechanism of Action and Literature Review. (PubMed, Clin Med Insights Case Rep) - "Initial ED therapy (IV fluids, ondansetron, metoclopramide, pantoprazole) produced minimal benefit; labs showed hypokalemic, hypochloremic metabolic alkalosis and pre-renal azotemia, with otherwise unremarkable imaging and enzymes. The effect is plausibly mediated by TRPV1 activation followed by peripheral desensitization, recapitulating the therapeutic hot-water response. Given consistent positive signals from case reports, series, and small pilot data, topical capsaicin is a low-risk, accessible adjunct for refractory CHS, but larger controlled studies are needed to define optimal dosing, duration, and long-term outcomes."

Journal • Metabolic Disorders • Nephrology • Pain

Comparison of ultrasound-guided erector spinae plane block to intrathecal morphine for postoperative analgesia in patients undergoing elective lumbar fusion operations under general anesthesia: a randomized controlled trial. (PubMed, BMC Anesthesiol) - P4 | "The analgesic effect of 0.2 mg intrathecal morphine after lumbar fusion operation under general anesthesia provided lower pain scores and lower analgesic demands than erector spinae plane block at the expense of a higher incidence of manageable side effects of intrathecal morphine within the first 24 h postoperatively. IRB: FMASU MD 102/2022."

Clinical • Journal • Anesthesia • CNS Disorders • Depression • Dermatology • Orthopedics • Pain • Pruritus • Psychiatry

Frequency and new-onset rates of nausea and fatigue in ¹⁷⁷Lu-PSMA therapy with standardized premedication. (PubMed, Nuklearmedizin) - "In this retrospective multicentre study, 67 mCRPC patients received 322 cycles of 177Lu-PSMA-617 at three Swiss centres. All patients received 8 mg dexamethasone and 8 mg ondansetron intravenously 30 minutes before therapy...However, new-onset rates of these two side effects were substantially lower after accounting for baseline symptoms. A protective effect of premedication with glucocorticoids and antiemetics could be the reason for this, but requires confirmation in prospective controlled studies."

Journal • Castration-Resistant Prostate Cancer • Fatigue • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Serratus Posterior Superior Plane Block for Postoperative Pain in Cardiac Surgery (clinicaltrials.gov) - P=N/A | N=50 | Recruiting | Sponsor: Ondokuz May?s University | Trial completion date: Apr 2026 ➔ Feb 2027 | Trial primary completion date: Feb 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Cardiovascular • Pain

MANTRA: Multimodal Anesthesia in Robotic Laparoscopic Nephrectomy (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: Fundacio Puigvert | Not yet recruiting ➔ Recruiting

Enrollment open • Anesthesia

EFFICACY OF ORAL VERSUS INTRAVENOUS ONDANSETRON AND DEXAMETHASONE AS ANTIEMETIC PROPHYLAXIS FOR PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (MASCC-ISOO 2026) - "Introduction The standard of care for highly emetogenic chemotherapy (HEC) is a four-drug regimen including a 5-HT3 receptor antagonist, dexamethasone, NK1R antagonist, and olanzapine as per guidelines. Conclusions Oral ondansetron and dexamethasone, used within a four-drug antiemetic regimen, are non-inferior, cost effective and easy to administer compared to IV regimen for CINV prevention without any added safety concern. These findings support adoption of oral antiemetics, particularly relevant for resource-limited settings and LMICs."

Clinical • Chemotherapy-Induced Nausea and Vomiting

Time to First Rescue Antiemetic With Ondansetron Plus Metoclopramide Versus Dexamethasone Plus Metoclopramide for PONV Prophylaxis in Laparoscopic Cholecystectomy (clinicaltrials.gov) - P4 | N=264 | Not yet recruiting | Sponsor: Faisalabad Medical University

Head-to-Head • New P4 trial

Aprepitant to Improve Same Day Discharge for TKA (clinicaltrials.gov) - P4 | N=350 | Not yet recruiting | Sponsor: Endeavor Health

New P4 trial • Orthopedics • Pain

Study on anaesthetic agent propofol and sevoflurane as maintenance agent along with anti-emetic drug ondansetron in reducing post operative nausea and vomiting in high-risk patients. (PubMed, BMC Anesthesiol) - "Ondansetron 4 mg IV administered pre-medication, combined with propofol induction and sevoflurane maintenance, effectively reduced early PONV incidence to 9.3% among high-risk adults. A higher incidence of PONV was observed in patients undergoing ENT procedures. These findings support the continued use of 4 mg as a sufficient and safe prophylactic dose for early postoperative periods, while underscoring the need for larger comparative studies evaluating dose-response relationships and late PONV outcomes."

Journal • Anesthesia

Effects of Rectal Indomethacin Suppository on Postoperative CRBD in Patients Undergoing LRP (clinicaltrials.gov) - P=N/A | N=130 | Recruiting | Sponsor: Zhejiang University

New trial • Anesthesia • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Multicenter Single Timepoint Kidney Dosimetry with Varying Imaging Protocols (SNMMI 2026) - "The German sites acquired SPECT/CT at 0.5, 24, 48, and 72 hours post-injection (p.i.), while the Australian site employed acquisitions at 0.5, 4, 24, and either 96 or 120 hours p.i. Patient preparation varied, with renal protection using lysine and arginine infusions (25-30 g over 3-4 hours) and antiemetic premedication with intravenous or oral ondansetron, with or without dexamethasone. The STP approach proposed by Madsen et al. showed slightly higher agreement for the D1 + D2 protocol compared to AUS, although this difference largely disappeared after stratification. Within the scope of this population-based STP model, extending the imaging window to very late time points did not provide a clear benefit for renal dose estimation."

Clinical

Multicenter Single Timepoint Kidney Dosimetry with Varying Imaging Protocols (SNMMI 2026) - "The German sites acquired SPECT/CT at 0.5, 24, 48, and 72 hours post-injection (p.i.), while the Australian site employed acquisitions at 0.5, 4, 24, and either 96 or 120 hours p.i. Patient preparation varied, with renal protection using lysine and arginine infusions (25-30 g over 3-4 hours) and antiemetic premedication with intravenous or oral ondansetron, with or without dexamethasone. The STP approach proposed by Madsen et al. showed slightly higher agreement for the D1 + D2 protocol compared to AUS, although this difference largely disappeared after stratification. Within the scope of this population-based STP model, extending the imaging window to very late time points did not provide a clear benefit for renal dose estimation."

Clinical

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting (clinicaltrials.gov) - P2/3 | N=200 | Recruiting | Sponsor: Montefiore Medical Center | Trial completion date: Jun 2026 ➔ Mar 2027 | Trial primary completion date: Jun 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date

Intravenous Versus Perineural Ondansetron for Laparoscopic Sleeve Gastrectomy (clinicaltrials.gov) - P=N/A | N=482 | Recruiting | Sponsor: Tanta University | N=170 ➔ 482

Enrollment change • Head-to-Head • Gastrointestinal Disorder